glp 1 for cats A biopharmaceutical company is looking ways to slim down household pets. Okava Pharmaceuticals, a San Francisco based company, is introducing a new GLP-1 clinical weight loss study for cats. MEOW-1, as Cornell launches clinical trial of

Not all of our clients are candidates for weight loss injections, depending on their medical history and general health, and some people may prefer to explore our non-medical weight loss program

Instead, their decreased food purchases are disproportionately concentrated in processed foods and sugar-sweetened beverages, further underscoring the shift in food preference induced by GLP-1R-based treatments (Dilley et al., 2025)

J Biol Chem 268:1965019655

(2019) and Perraudeau et al

These results are not guaranteed and should not be considered typical outcomes

Together, these observations suggest that receptor-level signaling and anti-inflammatory effects alone may be insufficient to produce functional improvement in energy-demanding tissues such as skeletal muscle and brain, where substrate turnover and mitochondrial metabolic throughput are critical determinants of tissue function